This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Stereotactic RT Alone or Followed by Niraparib for OMD or OPD in Ovarian Cancer Following PARPi Therapy - SOPRANO Trial

46 views
October 7, 2024
Comments 0
Login to view comments. Click here to Login